Literature DB >> 23011268

Disrupted-in-schizophrenia-1 Gln31Leu polymorphism results in social anhedonia associated with monoaminergic imbalance and reduction of CREB and β-arrestin-1,2 in the nucleus accumbens in a mouse model of depression.

Tatiana V Lipina1, Paul J Fletcher, Frankie H Lee, Albert H C Wong, John C Roder.   

Abstract

Disrupted-in-schizophrenia-1 (DISC1) is associated with mental disorders, including major depression. We previously showed that DISC1-Q31L mutant mice have depression-like behaviors and can therefore be used to study neurobiological mechanisms of depression and antidepressant (AD) medication action. First, we found reduced levels of dopamine, serotonin and norepinephrine in the nucleus accumbens (NAC) of DISC1-Q31L mutants. Next, we assessed social-conditioned place preference as a reward-dependent task and the capacity of distinct ADs to correct impaired social behavior in DISC1-Q31L mice. Bupropion, but not fluoxetine or desipramine, was able to correct deficient social facilitation, social reward, and social novelty in DISC1-Q31L mutants, whereas all three ADs were able to improve social motivation and behavioral despair in DISC1-Q31L mutants. Furthermore, we sought to correlate social anhedonia with molecular and cellular features including dendritic spine density, β-arrestin-1,2, and cAMP-response-element-binding protein (CREB) in the NAC as biomarkers related to depression and the DISC1 pathway. DISC1-Q31L mutants showed reduced levels of β-arrestin-1,2, CREB, and spine density in the NAC, further supporting the construct validity of the genetic model. Bupropion induced the greatest effect on CREB in DISC1-Q31L mutants, whereas all studied ADs corrected the reduced levels of β-arrestin-1,2 and modestly ameliorated deficient spine density in this brain region. Overall, we find neurobiological changes accompanying social anhedonia in the NAC of DISC1-Q31L mutant mice, consistent with a role for DISC1 in regulating social reward as an endophenotype of depression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23011268      PMCID: PMC3547193          DOI: 10.1038/npp.2012.197

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  74 in total

1.  The grooming behavior of the chimpanzee as a reinforcer.

Authors:  J L FALK
Journal:  J Exp Anal Behav       Date:  1958-01       Impact factor: 2.468

Review 2.  The Akt-GSK-3 signaling cascade in the actions of dopamine.

Authors:  Jean-Martin Beaulieu; Raul R Gainetdinov; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2007-03-08       Impact factor: 14.819

3.  DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses.

Authors:  Vincent Vialou; Alfred J Robison; Quincey C Laplant; Herbert E Covington; David M Dietz; Yoshinori N Ohnishi; Ezekiell Mouzon; Augustus J Rush; Emily L Watts; Deanna L Wallace; Sergio D Iñiguez; Yoko H Ohnishi; Michel A Steiner; Brandon L Warren; Vaishnav Krishnan; Carlos A Bolaños; Rachael L Neve; Subroto Ghose; Olivier Berton; Carol A Tamminga; Eric J Nestler
Journal:  Nat Neurosci       Date:  2010-05-16       Impact factor: 24.884

Review 4.  β-arrestin-biased signaling by the β-adrenergic receptors.

Authors:  Sudha K Shenoy
Journal:  Curr Top Membr       Date:  2011       Impact factor: 3.049

5.  Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments.

Authors:  Julieta Alfonso; Luciana R Frick; Dafne M Silberman; María L Palumbo; Ana M Genaro; Alberto C Frasch
Journal:  Biol Psychiatry       Date:  2005-09-02       Impact factor: 13.382

Review 6.  The other face of depression, reduced positive affect: the role of catecholamines in causation and cure.

Authors:  David Nutt; Koen Demyttenaere; Zoltan Janka; Trond Aarre; Michel Bourin; Pier Luigi Canonico; Jose Luis Carrasco; Steven Stahl
Journal:  J Psychopharmacol       Date:  2006-10-18       Impact factor: 4.153

Review 7.  Monoamine dysfunction and the pathophysiology and treatment of depression.

Authors:  D S Charney
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

8.  Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling.

Authors:  Yingwei Mao; Xuecai Ge; Christopher L Frank; Jon M Madison; Angela N Koehler; Mary Kathryn Doud; Carlos Tassa; Erin M Berry; Takahiro Soda; Karun K Singh; Travis Biechele; Tracey L Petryshen; Randall T Moon; Stephen J Haggarty; Li-Huei Tsai
Journal:  Cell       Date:  2009-03-20       Impact factor: 41.582

Review 9.  DISC1-binding proteins in neural development, signalling and schizophrenia.

Authors:  Nicholas J Bradshaw; David J Porteous
Journal:  Neuropharmacology       Date:  2010-12-31       Impact factor: 5.250

10.  Anhedonia in schizophrenia and major depression: state or trait?

Authors:  Lorenzo Pelizza; Alberto Ferrari
Journal:  Ann Gen Psychiatry       Date:  2009-10-08       Impact factor: 3.455

View more
  12 in total

1.  Association study of three single-nucleotide polymorphisms in the cyclic adenosine monophosphate response element binding 1 gene and major depressive disorder.

Authors:  Yange Wei; Shufang Bu; Xican Liu; Hengfen Li
Journal:  Exp Ther Med       Date:  2015-04-03       Impact factor: 2.447

Review 2.  Astrocyte Bioenergetics and Major Psychiatric Disorders.

Authors:  Ivan V Maly; Michael J Morales; Mikhail V Pletnikov
Journal:  Adv Neurobiol       Date:  2021

Review 3.  Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia.

Authors:  Christina A Wilson; James I Koenig
Journal:  Eur Neuropsychopharmacol       Date:  2013-11-26       Impact factor: 4.600

4.  Facilitating mGluR4 activity reverses the long-term deleterious consequences of chronic morphine exposure in male mice.

Authors:  Jerome A J Becker; Lucie P Pellissier; Yannick Corde; Thibaut Laboute; Audrey Léauté; Jorge Gandía; Julie Le Merrer
Journal:  Neuropsychopharmacology       Date:  2020-12-21       Impact factor: 8.294

5.  Insights into the origin of DNA methylation differences between monozygotic twins discordant for schizophrenia.

Authors:  Melkaye G Melka; Christina A Castellani; Richard O'Reilly; Shiva M Singh
Journal:  J Mol Psychiatry       Date:  2015-06-26

Review 6.  The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review.

Authors:  T Dahoun; S V Trossbach; N J Brandon; C Korth; O D Howes
Journal:  Transl Psychiatry       Date:  2017-01-31       Impact factor: 6.222

Review 7.  Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models.

Authors:  James N Samsom; Albert H C Wong
Journal:  Front Psychiatry       Date:  2015-02-18       Impact factor: 4.157

8.  Locus Ceruleus Norepinephrine Release: A Central Regulator of CNS Spatio-Temporal Activation?

Authors:  Marco Atzori; Roberto Cuevas-Olguin; Eric Esquivel-Rendon; Francisco Garcia-Oscos; Roberto C Salgado-Delgado; Nadia Saderi; Marcela Miranda-Morales; Mario Treviño; Juan C Pineda; Humberto Salgado
Journal:  Front Synaptic Neurosci       Date:  2016-08-26

9.  Behavioral Changes in Mice Lacking Interleukin-33.

Authors:  Eisuke Dohi; Eric Y Choi; Indigo V L Rose; Akiho S Murata; Sharon Chow; Minae Niwa; Shin-Ichi Kano
Journal:  eNeuro       Date:  2017-12-26

10.  The Altered Supramolecular Structure of Dopamine D2 Receptors in Disc1-deficient Mice.

Authors:  Taichi Onishi; Hirokazu Sakamoto; Shigeyuki Namiki; Kenzo Hirose
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.